Impact of Circadian Rhythm on Immunotherapy
NCT07224971
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
350
Enrollment
OTHER
Sponsor class
Conditions
Advanced/Metastatic NSCLC
Interventions
DRUG:
Immunotherapy - PD-1 Blocker
Sponsor
Liza Villaruz, MD